Lineage Cell Therapeutics Inc (LCTX) is not a strong buy for a beginner investor with a long-term strategy at this time. While the technical indicators show some bullish trends, the lack of significant positive catalysts, weak financial performance, and absence of strong trading signals suggest that holding off on this investment is a more prudent choice.

Technical Analysis

The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.0248), indicating upward momentum. However, the RSI is neutral at 77.568, and the stock is trading near resistance levels (R1: 1.934, R2: 2.021), suggesting limited immediate upside potential.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market, but the overall volume is not significant enough to drive a strong directional bias.

Technical Summary

Sell

Buy

Positive Catalysts

The MACD and moving averages indicate a short-term bullish trend. Gross margin increased slightly to 99.86%, showing operational efficiency.

Neutral/Negative Catalysts

Revenue dropped by -2.59% YoY in Q3 2025, and the company remains unprofitable with a net income of -$29.78M. No recent news or significant insider or hedge fund activity to support a bullish case. The stock has a 60% chance of declining over the next week and month based on historical patterns.

Financial Performance

In Q3 2025, revenue declined by -2.59% YoY to $3.68M. Despite an improvement in net income (-$29.78M, up 881.58% YoY) and EPS (-0.13, up 550% YoY), the company remains unprofitable. Gross margin increased slightly to 99.86%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on recent analyst ratings or price target changes. Wall Street sentiment appears neutral with no strong pros or cons.

4 Analyst Rating

Wall Street analysts forecast LCTX stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.890

Low

Averages

4.5

High

Current: 1.890

Low

Averages

4.5

High

H.C. Wainwright

Buy

maintain

AI Analysis

2025-11-24

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-11-24

maintain

Buy

Reason

H.C. Wainwright reiterated a Buy rating and $9 price target on Lineage Cell Therapeutics (LCTX), saying the major breakout event the firm is looking for is visibility out of global partner Roche (RHHBY) regarding OpRegen data and next steps. Monday's $5M milestone represents yet another tangible piece of evidence for Roche's progress in the OpRegen program for which they have global rights for dry-AMD and geographic atrophy, the analyst tells investors in a research note. The firm added that data, anecdotes, and comps provide significant support that OpRegen is moving into later studies in Roche's hands.

B. Riley Securities

Mayank Mamtani

Strong Buy

Maintains

$4 → $3

2025-03-14

Reason

B. Riley Securities

Mayank Mamtani

Price Target

$4 → $3

2025-03-14

Maintains

Strong Buy

Reason

B. Riley analyst Mayank Mamtani lowered the firm's price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the shares. Lineage Cell Therapeutics' Q4 recap focused on Roche (RHHBY)-partnered OpRegen program, steadily advancing earlier-stage wholly-owned programs, and Lineage's dominant position in large-scale allogeneic manufacturing to produce millions of retinal pigment epithelium cells, the analyst tells investors in a research note. The OpRegen dry AMD opportunity could come through the ongoing Phase II GAlette study interim data release, and Roche opting to progress to a randomized controlled study to confirm high efficacy benefits noted with optimized delivery system in sizeable patient population, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LCTX

Unlock Now

LCTX Should I Buy

LCTX Should I Buy

Should You Buy Lineage Cell Therapeutics Inc (LCTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch